Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 31 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Financial Performance: Daiichi Sankyo reported a 16.6% year-on-year revenue increase to ¥1,367.6 billion for Q3 FY2024, primarily driven by strong sales of ENHERTU, which rose by ¥128.4 billion to ¥404.4 billion, and an upward revision of its global product sales forecast for ENHERTU to ¥539.9 billion for FY2024.
Outlook and Challenges: Despite delays in Datroway's approvals affecting future projections, management remains optimistic about sustaining growth through ENHERTU and has set a R&D spending target of ¥530 billion for FY2025, while addressing concerns over profitability pressures from vaccine sales uncertainties and high costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
